News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Eli Lilly acquired rights to a technology from Entos Pharmaceuticals that boosts the development of nucleic acid therapeutics for the central and peripheral nervous system.
Formerly Esker Therapeutics, a San Francisco-based biotech company, now named Alumis, closed on a $200 million Series B financing round to help advance its precision immunology medicines.
The acquisition is expected to bolster Odyssey’s drug development capabilities in immunology and oncology.
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical’s jointly prepared treatment for Angelman syndrome have been provided a green single by DSMB recently.
The NASH trial achieved the primary endpoint of proton density fat fraction and the secondary endpoint of cT1.
An improvement in cUHDRS was observed in more than half of all evaluable patients and was specifically seen in 75% of the evaluable population who showed excess complement activity at baseline.
Intellia and Kyverna announced an exclusive agreement to develop and later commercialize an allogeneic CD19 CAR T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses.
A billion-dollar real estate project is coming to Morrisville, NC, as developers hope to capitalize on the growing biotechnology industry in the state’s Research Triangle.
Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.
It’s been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.